SCHEMBL366071

SCHEMBL366071

COc1ccc(Cn2cc3c(n2)CC(O)CCC3=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.40
PTGS2 P35354 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HKDC1 Q2TB90 1/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
CMA1 P23946 1/20 0.38
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 1/20 0.37
HDAC1 Q13547 1/20 0.37
CYP3A4 P08684 1/20 0.37
GAA P10253 1/20 0.37
GSK3A P49840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7670133 0.87 AADAT (0.47) AADATSMN1; SMN2ALDH1A1POLBPTGS2
SCHEMBL365744 0.87 AADAT (0.47) AADATSMN1; SMN2ALDH1A1POLBHCRTR1
SCHEMBL6837301 0.82 ALDH1A1 (0.48) AADATSMN1; SMN2ALDH1A1POLBCMA1
SCHEMBL365659 0.82 ALDH1A1 (0.48) AADATSMN1; SMN2ALDH1A1POLBCMA1
SCHEMBL365560 0.82 AADAT (0.44) AADATSMN1; SMN2ALDH1A1POLBMAPK1
SCHEMBL29191592 0.81 AADAT (0.51) AADATSMN1; SMN2ALDH1A1POLBCMA1
SCHEMBL29191609 0.81 AADAT (0.51) AADATSMN1; SMN2ALDH1A1POLBCMA1
SCHEMBL15182504 0.79 AADAT (0.46) AADATPTGS2KDM4EHKDC1HCRTR1
SCHEMBL366655 0.79 AADAT (0.46) AADATSMN1; SMN2ALDH1A1POLBCMA1
SCHEMBL15182499 0.76 AADAT (0.47) AADATSMN1; SMN2ALDH1A1POLBHCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865988-A Tetrafused ring compound, preparation method and application thereof 厦门宝太生物科技股份有限公司 2024-04-12 CN disclosed
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
US-20130210807-A1 Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. MERCK SHARP & DOHME CORP. 2013-08-15 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012006760-A1 TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012008999-A2 TRICYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210807-A1 Tricyclic Compounds as Allosteric Modulators of Metabotropic Glutamate Receptors. GRM3, GRM6, GRM1 AADAT 3254/4885SMN1; SMN2 3831/4885ALDH1A1 3550/4885
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885SMN1; SMN2 2061/4885ALDH1A1 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.